Needham Maintains Buy on AtriCure, Raises Price Target to $70
Benzinga 11 hours ago
Analyst RatingsNewsPrice Target
Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $64 to $70.
Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $64 to $70.